Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Animal Mitochondrial Genetics

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...

EDTA: Auxiliary Complexing Reagents

EDTA: Auxiliary Complexing Reagents

EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...

EDTA: Conditional Formation Constant

EDTA: Conditional Formation Constant

Each EDTA molecule has six binding sites: four carboxyl groups and two amino groups. The fully protonated form of EDTA is represented as H6Y2+. However, it can exist in different forms, H5Y+, H4Y, H3Y−, H2Y2−, and HY3−, depending on the pH of the solution. In very basic solutions with pH > 10.17, the fully deprotonated form, Y4−, is the predominant species that readily complexes with metal ions in a 1:1 ratio.
For the equilibrium reaction of the metal with the Y4− form of EDTA, the formation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.

The oncologist·2022

Same author

Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells.

Nature biotechnology·2015

Same author

AML genomics: introduction.

Seminars in hematology·2014

Same author

AML genomics for the clinician.

Seminars in hematology·2014

Same author

Genetics of myelodysplastic syndromes: new insights.

Hematology. American Society of Hematology. Education Program·2011

Same author

Therapy-related myelodysplastic syndrome: models and genetics.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2009

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

AML1 and Evi1: coconspirators in MDS/AML?

Timothy Graubert¹

¹Washington University School of Medicine, USA.

|April 25, 2008

Summary

Mutant AML1 (RUNX1) alleles initiate myelodysplastic syndrome (MDS) and progress to acute myelogenous leukemia (AML). This occurs with Evi1 overexpression in a mouse model, offering insights into leukemia development.

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
Acute myelogenous leukemia (AML) is a heterogeneous malignancy arising from hematopoietic stem and progenitor cells.

Discussion:

This study investigates the role of mutant AML1 (RUNX1) alleles in MDS and AML development.
The research utilizes a mouse bone marrow transplantation model to explore leukemogenesis.
Overexpression of Evi1 is identified as a key factor in the progression from MDS to AML.

Key Insights:

Mutant AML1 (RUNX1) alleles can initiate myelodysplastic syndrome (MDS).
MDS initiated by mutant AML1 (RUNX1) can progress to acute myelogenous leukemia (AML).
Evi1 overexpression is associated with the progression of MDS to AML.

Related Experiment Videos

Last Updated: Jul 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Outlook:

Further research into the AML1-Evi1 axis may reveal novel therapeutic targets for MDS and AML.
Understanding the molecular mechanisms underlying leukemic transformation is crucial for developing effective treatments.
This study provides a foundation for exploring the role of RUNX1 mutations in myeloid malignancies.